These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 12412670

  • 1. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.
    Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC.
    Eur Respir J; 2002 Oct; 20(4):819-25. PubMed ID: 12412670
    [Abstract] [Full Text] [Related]

  • 2. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.
    Miller DP, Watkins SE, Sampson T, Davis KJ.
    Phys Sportsmed; 2010 Dec; 38(4):19-27. PubMed ID: 21150138
    [Abstract] [Full Text] [Related]

  • 3. Survival in COPD patients after regular use of fluticasone propionate and salmeterol.
    Marchand E.
    Eur Respir J; 2003 Mar; 21(3):559-60; author reply 560. PubMed ID: 12662020
    [No Abstract] [Full Text] [Related]

  • 4. The TORCH (towards a revolution in COPD health) survival study protocol.
    Vestbo J, TORCH Study Group.
    Eur Respir J; 2004 Aug; 24(2):206-10. PubMed ID: 15332386
    [Abstract] [Full Text] [Related]

  • 5. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ, Cates CJ, Poole P.
    Cochrane Database Syst Rev; 2013 May 31; (5):CD007891. PubMed ID: 23728670
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database.
    Miller DP, Watkins SE, Sampson T, Davis KJ.
    Int J Chron Obstruct Pulmon Dis; 2011 May 31; 6():467-76. PubMed ID: 22003292
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline.
    Dal Negro RW, Pomari C, Tognella S, Micheletto C.
    Pulm Pharmacol Ther; 2003 May 31; 16(4):241-6. PubMed ID: 12850128
    [Abstract] [Full Text] [Related]

  • 10. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ, Cates CJ, Poole P.
    Cochrane Database Syst Rev; 2010 May 12; (5):CD007891. PubMed ID: 20464758
    [Abstract] [Full Text] [Related]

  • 11. Additive effects of salmeterol and fluticasone or theophylline in COPD.
    Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S.
    Chest; 2000 Dec 12; 118(6):1576-81. PubMed ID: 11115442
    [Abstract] [Full Text] [Related]

  • 12. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.
    Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT.
    Respir Res; 2014 Sep 24; 15(1):105. PubMed ID: 25248764
    [Abstract] [Full Text] [Related]

  • 13. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Rousseau R, ABC (Advair, Biomarkers in COPD) Investigators.
    BMC Pulm Med; 2006 Feb 06; 6():3. PubMed ID: 16460562
    [Abstract] [Full Text] [Related]

  • 14. Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.
    Lyseng-Williamson KA, Keating GM.
    Am J Respir Med; 2002 Feb 06; 1(4):273-82; discussion 283-4. PubMed ID: 14720047
    [Abstract] [Full Text] [Related]

  • 15. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 16. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
    Markham A, Jarvis B.
    Drugs; 2000 Nov 22; 60(5):1207-33. PubMed ID: 11129128
    [Abstract] [Full Text] [Related]

  • 17. Salmeterol/fluticasone combination in the treatment of COPD.
    Chung KF.
    Int J Chron Obstruct Pulmon Dis; 2006 Nov 22; 1(3):235-42. PubMed ID: 18046860
    [Abstract] [Full Text] [Related]

  • 18. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M, Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.
    Ann Intern Med; 2007 Apr 17; 146(8):545-55. PubMed ID: 17310045
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 17; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.